Found: 13
Select item for more details and to access through your institution.
The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3465, doi. 10.1111/dom.15244
- By:
- Publication type:
- Article
The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3453, doi. 10.1111/dom.15145
- By:
- Publication type:
- Article
T he R eal‐World O bservational P rospective Study of H ealth Outcomes with Dulaglut i de and Liraglutide in Patients with Typ e 2 Diabete s (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2373, doi. 10.1111/dom.14823
- By:
- Publication type:
- Article
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 631, doi. 10.1111/dom.14615
- By:
- Publication type:
- Article
Cover Image, Volume 22, Issue 3.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 1, doi. 10.1111/dom.13999
- By:
- Publication type:
- Article
Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 355, doi. 10.1111/dom.13902
- By:
- Publication type:
- Article
Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2570, doi. 10.1111/dom.13844
- By:
- Publication type:
- Article
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 2023, doi. 10.1111/dom.13313
- By:
- Publication type:
- Article
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 7, p. 1929, doi. 10.1007/s13300-021-01076-0
- By:
- Publication type:
- Article
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 10, p. 2383, doi. 10.1007/s13300-020-00908-9
- By:
- Publication type:
- Article
Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
- Published in:
- Quality of Life Research, 2021, v. 30, n. 7, p. 2033, doi. 10.1007/s11136-021-02808-2
- By:
- Publication type:
- Article
Adherence to Therapies in Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2013, v. 4, n. 2, p. 175, doi. 10.1007/s13300-013-0034-y
- By:
- Publication type:
- Article
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.
- Published in:
- Drugs in R&D, 2019, v. 19, n. 2, p. 213, doi. 10.1007/s40268-019-0273-0
- By:
- Publication type:
- Article